– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment –
– CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing –
– MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 –
– Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 –
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, highlights updated clinical data from the ongoing MGTA-117 Phase 1/2 dose-escalation clinical trial made in an oral presentation today at the American Society of Hematology 2022 Annual (ASH) Meeting in New Orleans and provides program updates across the portfolio.
